The role of autoantibodies in multiple sclerosis (MS) has been enigmatic since the first description, many decades ago, of intrathecal immunoglobulin production in people with this condition. Some studies have indicated that MS pathology is heterogeneous, with an antibody-associated subtype — characterized by B cells (in varying quantities), antibodies and complement — existing alongside other subtypes with different pathologies. However, subsequent evidence suggested that some cases originally diagnosed as MS with autoantibody-mediated demyelination were more likely to be neuromyelitis optica spectrum disorder or myelin oligodendrocyte glycoprotein antibody-associated disease. These findings raise the important question of whether an autoantibody-mediated MS subtype exists and whether pathogenic MS-associated autoantibodies remain to be identified. Potential roles of autoantibodies in MS could range from specific antibodies defining the disease to a non-disease-specific amplification of cellular immune responses and other pathophysiological processes. In this Perspective, we review studies that have attempted to identify MS-associated autoantibodies and provide our opinions on their possible roles in the pathophysiology of MS.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Frohman, E. M., Racke, M. K. & Raine, C. S. Multiple sclerosis–the plaque and its pathogenesis. N. Engl. J. Med. 354, 942–955 (2006).
Lassmann, H., Bruck, W. & Lucchinetti, C. F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17, 210–218 (2007).
Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683–747 (2005).
Reindl, M., Khalil, M. & Berger, T. Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. 180, 50–62 (2006).
Kuenz, B. et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 3, e2559 (2008).
Cepok, S. et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124, 2169–2176 (2001).
Freedman, M. S. et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol. 62, 865–870 (2005).
Berger, T. & Reindl, M. Antibody biomarkers in CNS demyelinating diseases–a long and winding road. Eur. J. Neurol. 22, 1162–1168 (2015).
Hohlfeld, R., Dornmair, K., Meinl, E. & Wekerle, H. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol. 15, 317–331 (2016).
Schirmer, L., Srivastava, R. & Hemmer, B. To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult. Scler. 20, 271–279 (2014).
Hardy, T. A. et al. Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol. 15, 967–981 (2016).
Dalmau, J. & Graus, F. Antibody-mediated encephalitis. N. Engl. J. Med. 378, 840–851 (2018).
Marignier, R. et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 20, 762–772 (2021).
Jarius, S. et al. Neuromyelitis optica. Nat. Rev. Dis. Prim. 6, 85 (2020).
Pruss, H. Autoantibodies in neurological disease. Nat. Rev. Immunol. 21, 798–813 (2021).
Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707–717 (2000).
Tobin, W. O. et al. Clinical correlation of multiple sclerosis immunopathologic subtypes. Neurology 97, e1906–e1913 (2021).
Prineas, J. W. & Graham, J. S. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann. Neurol. 10, 149–158 (1981).
Barnett, M. H., Parratt, J. D., Cho, E. S. & Prineas, J. W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann. Neurol. 65, 32–46 (2009).
Henderson, A. P., Barnett, M. H., Parratt, J. D. & Prineas, J. W. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 66, 739–753 (2009).
Michailidou, I. et al. Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: implication for disease pathogenesis. Glia 65, 264–277 (2017).
Werneburg, S. et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity 52, 167–182.e7 (2020).
Bornstein, M. B. & Appel, S. H. Tissue culture studies of demyelination. Ann. N. Y. Acad. Sci. 122, 280–286 (1965).
Appel, S. H. & Bornstein, M. B. The application of tissue culture to the study of experimental allergic encephalomyelitis. II. Serum factors responsible for demyelination. J. Exp. Med. 119, 303–312 (1964).
Grundke-Iqbal, I. & Bornstein, M. B. Multiple sclerosis: serum gamma globulin and demyelination in organ culture. Neurology 30, 749–754 (1980).
Seil, F. J. Myelin antigens and antimyelin antibodies. Antibodies 7, 2 (2018).
Lisak, R. P. et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J. Neuroimmunol. 246, 85–95 (2012).
Linington, C., Webb, M. & Woodhams, P. L. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J. Neuroimmunol. 6, 387–396 (1984).
Brunner, C., Lassmann, H., Waehneldt, T. V., Matthieu, J. M. & Linington, C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J. Neurochem. 52, 296–304 (1989).
Lassmann, H. & Bradl, M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 133, 223–244 (2017).
Lucchinetti, C. F. et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125, 1450–1461 (2002).
Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106–2112 (2004).
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473–477 (2005).
Bennett, J. L. et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 66, 617–629 (2009).
Bradl, M. et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66, 630–643 (2009).
Saadoun, S. et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349–361 (2010).
Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177–189 (2015).
Lucchinetti, C. F. et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 24, 83–97 (2014).
Jarius, S. et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J. Neuroinflamm. 15, 134 (2018).
Lopez-Chiriboga, A. S. et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 75, 1355–1363 (2018).
Reindl, M. & Waters, P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat. Rev. Neurol. 15, 89–102 (2019).
Jarius, S. et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult. Scler. 22, 1541–1549 (2016).
Ricken, G. et al. Detection methods for autoantibodies in suspected autoimmune encephalitis. Front. Neurol. 9, 841 (2018).
Waters, P., Pettingill, P. & Lang, B. Detection methods for neural autoantibodies. Handb. Clin. Neurol. 133, 147–163 (2016).
O’Connor, K. C. et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J. Neuroimmunol. 136, 140–148 (2003).
Srivastava, R. et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367, 115–123 (2012).
Brickshawana, A. et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 13, 795–806 (2014).
Nerrant, E. et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult. Scler. 20, 1699–1703 (2014).
Probstel, A. K. et al. Multiple sclerosis and antibodies against KIR4.1. N. Engl. J. Med. 374, 1496–1498 (2016).
Chastre, A., Hafler, D. A. & O’Connor, K. C. Evaluation of KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 374, 1495–1496 (2016).
Higuchi, O. et al. Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO. Neurol. Neuroimmunol. Neuroinflamm. 3, e263 (2016).
Navas-Madronal, M. et al. Absence of antibodies against KIR4.1 in multiple sclerosis: a three-technique approach and systematic review. PLoS ONE 12, e0175538 (2017).
Mathey, E. K. et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 204, 2363–2372 (2007).
Devaux, J. J. et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86, 800–807 (2016).
Sokmen, O., Demirci, M. & Tan, E. A case with neurofascin-155 IgG antibody-associated combined central and peripheral demyelination: successfully treated with anti-CD20 monoclonal antibody. Clin. Neurol. Neurosurg. 210, 106961 (2021).
Verghese, A., Krishnan, D., Chia, Y. K., Querol, L. & Hiew, F. L. Optic nerve demyelination in IgG4 anti-neurofascin 155 antibody-positive combined central and peripheral demyelination syndrome. J. Cent. Nerv. Syst. Dis. 13, 11795735211039913 (2021).
Elliott, C. et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 135, 1819–1833 (2012).
Owens, G. P. et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 65, 639–649 (2009).
Blauth, K. et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol. 130, 765–781 (2015).
Liu, Y. et al. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol. Commun. 5, 25 (2017).
Brennan, K. M. et al. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J. Neuroimmunol. 238, 87–95 (2011).
Menon, K. K., Piddlesden, S. J. & Bernard, C. C. Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin. J. Neurochem. 69, 214–222 (1997).
Fierz, W. et al. Synergism in the pathogenesis of EAE induced by an MBP-specific T-cell line and monoclonal antibodies to galactocerebroside or a myelin oligodendroglial glycoprotein. Ann. N. Y. Acad. Sci. 540, 360–363 (1988).
Menge, T. et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J. Allergy Clin. Immunol. 116, 453–459 (2005).
Breij, E. C. et al. Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. J. Neuroimmunol. 176, 106–114 (2006).
Lily, O., Palace, J. & Vincent, A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 127, 269–279 (2004).
Rivas, J. R. et al. Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathol. 133, 43–60 (2017).
Miyachi, Y. et al. Serum anti-oligodendrocyte autoantibodies in patients with multiple sclerosis detected by a tissue-based immunofluorescence assay. Front. Neurol. 12, 681980 (2021).
Sun, X. et al. Quantified CSF antibody reactivity against myelin in multiple sclerosis. Ann. Clin. Transl. Neurol. 2, 1116–1123 (2015).
Brändle, S. M. et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc. Natl Acad. Sci. USA 113, 7864–7869 (2016).
Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321–327 (2022).
Shimizu, F. et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci. Transl. Med. 9, eaai9111 (2017).
Shimizu, F. et al. GRP78 antibodies are associated with blood-brain barrier breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder. Neurol. Neuroimmunol. Neuroinflamm. 9, e1038 (2022).
Linington, C., Bradl, M., Lassmann, H., Brunner, C. & Vass, K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130, 443–454 (1988).
Vass, K., Heininger, K., Schafer, B., Linington, C. & Lassmann, H. Interferon-γ potentiates antibody-mediated demyelination in vivo. Ann. Neurol. 32, 198–206 (1992).
Spadaro, M. et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann. Neurol. 84, 315–328 (2018).
Beltran, E. et al. Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis. Acta Neuropathol. 141, 67–83 (2021).
Hillebrand, S. et al. Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol. 137, 467–485 (2019).
Pellerin, K. et al. MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response. Brain 144, 2361–2374 (2021).
Carta, S. et al. Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol. 141, 801–804 (2021).
Dubois-Dalcq, M., Niedieck, B. & Buyse, M. Action of anti-cerebroside sera on myelinated nervous tissue cultures. Pathol. Eur. 5, 331–347 (1970).
Seil, F. J. & Agrawal, H. C. Myelin-proteolipid protein does not induce demyelinating or myelination-inhibiting antibodies. Brain Res. 194, 273–277 (1980).
Piddlesden, S., Lassmann, H., Laffafian, I., Morgan, B. P. & Linington, C. Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin. Exp. Immunol. 83, 245–250 (1991).
Piddlesden, S. J., Lassmann, H., Zimprich, F., Morgan, B. P. & Linington, C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 143, 555–564 (1993).
Iorio, R. et al. Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J. Autoimmun. 40, 21–27 (2013).
Owens, G. P. et al. Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG. J. Biol. Chem. 290, 12123–12134 (2015).
Peschl, P. et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J. Neuroinflamm. 14, 208 (2017).
Hoftberger, R. et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 139, 875–892 (2020).
Takai, Y. et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143, 1431–1446 (2020).
Macrini, C. et al. Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain 144, 2375–2389 (2021).
Titulaer, M. J. et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann. Neurol. 75, 411–428 (2014).
Zrzavy, T. et al. Neuropathological variability within a spectrum of NMDAR-encephalitis. Ann. Neurol. 90, 725–737 (2021).
Hughes, E. G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 30, 5866–5875 (2010).
Matute, C. et al. N-methyl-D-aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function. Ann. Neurol. 87, 670–676 (2020).
Phillips, O. R. et al. Superficial white matter damage in anti-NMDA receptor encephalitis. J. Neurol. Neurosurg. Psychiatry 89, 518–525 (2018).
Koneczny, I. et al. IgG4 autoantibodies in organ-specific autoimmunopathies: reviewing class switching, antibody-producing cells, and specific immunotherapies. Front. Immunol. 13, 834342 (2022).
Bhat, M. A. et al. Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin. Neuron 30, 369–383 (2001).
Boyle, M. E. et al. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron 30, 385–397 (2001).
Sherman, D. L. et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 48, 737–742 (2005).
Pomicter, A. D. et al. Novel forms of neurofascin 155 in the central nervous system: alterations in paranodal disruption models and multiple sclerosis. Brain 133, 389–405 (2010).
Manso, C. et al. Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. J. Clin. Invest. 129, 2222–2236 (2019).
Kinzel, S. et al. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol. 132, 43–58 (2016).
Flach, A. C. et al. Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proc. Natl Acad. Sci. USA 113, 3323–3328 (2016).
Breij, E. C. et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 63, 16–25 (2008).
Levin, M. C. et al. Autoantibodies to non-myelin antigens as contributors to the pathogenesis of multiple sclerosis. J. Clin. Cell. Immunol. https://doi.org/10.4172/2155-9899.1000148 (2013).
Puentes, F. et al. Neurofilament light as an immune target for pathogenic antibodies. Immunology 152, 580–588 (2017).
Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017).
Cubas-Nunez, L. et al. Potential role of CHI3L1+ astrocytes in progression in MS. Neurol. Neuroimmunol. Neuroinflamm. 8, e972 (2021).
van der Poel, M., Hoepel, W., Hamann, J., Huitinga, I. & Dunnen, J. D. IgG immune complexes break immune tolerance of human microglia. J. Immunol. 205, 2511–2518 (2020).
Robinson, W. H. et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 8, 295–301 (2002).
Robinson, W. H. et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21, 1033–1039 (2003).
Kanter, J. L. et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12, 138–143 (2006).
Van Haren, K. et al. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult. Scler. 19, 1726–1733 (2013).
Quintana, F. J. et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl Acad. Sci. USA 105, 18889–18894 (2008).
Quintana, F. J. et al. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology 78, 532–539 (2012).
Metz, I. et al. Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e204 (2016).
Stork, L. et al. Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. Acta Neuropathol. 139, 547–564 (2020).
Kuerten, S. et al. Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. Proc. Natl Acad. Sci. USA 117, 21512–21518 (2020).
Bakshi, R. et al. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e200 (2016).
Lucchinetti, C. F., Bruck, W., Rodriguez, M. & Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259–274 (1996).
Storch, M. K. et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43, 465–471 (1998).
Metz, I. et al. Magnetic resonance imaging correlates of multiple sclerosis immunopathological patterns. Ann. Neurol. 90, 440–454 (2021).
Lucchinetti, C. F. et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131, 1759–1775 (2008).
Di Gregorio, M. et al. Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study. Eur. J. Neurol. 28, 1299–1307 (2021).
Keegan, M. et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366, 579–582 (2005).
Jarius, S. et al. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J. Neuroinflamm. 14, 171 (2017).
Torkildsen, O. et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol. 20, 720–729 (2010).
Brink, B. P. et al. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol. 64, 147–155 (2005).
Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188–2197 (2011).
Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391–404 (2016).
Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat. Protoc. 12, 828–863 (2017).
Paul, F. et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 4, e133 (2007).
Tanaka, M., Tanaka, K., Komori, M. & Saida, T. Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J. Neurol. Neurosurg. Psychiatry 78, 990–992 (2007).
Mader, S. et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS ONE 5, e10455 (2010).
Waters, P. et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 87, 1005–1015 (2016).
Long, Y. et al. Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. J. Neuroimmunol. 273, 103–110 (2014).
Tzartos, J. S. et al. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS ONE 8, e74773 (2013).
Schanda, K. et al. Antibodies to aquaporin-1 are not present in neuromyelitis optica. Neurol. Neuroimmunol. Neuroinflamm. 2, e160 (2015).
Flanagan, E. P. et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann. Neurol. 81, 298–309 (2017).
Quintana, F. J. et al. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology 83, 2219–2226 (2014).
Sadaba, M. C. et al. Serum antibodies to phosphatidylcholine in MS. Neurol. Neuroimmunol. Neuroinflamm. 7, e765 (2020).
Amor, S. et al. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Mult. Scler. 20, 1355–1362 (2014).
Ramberger, M. et al. NMDA receptor antibodies: a rare association in inflammatory demyelinating diseases. Neurol. Neuroimmunol. Neuroinflamm. 2, e141 (2015).
Bar-Or, A. et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 64, 1407–1415 (2007).
O’Connor, K. C. et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 13, 211–217 (2007).
Ousman, S. S. et al. Protective and therapeutic role for αB-crystallin in autoimmune demyelination. Nature 448, 474–479 (2007).
Tengvall, K. et al. Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc. Natl Acad. Sci. USA 116, 16955–16960 (2019).
The research of R.H. is supported by research grants from the Austrian Science Funds (FWF; project I4685-B SYNABS; DOC 33-B27 and I3334-B27 SILENCE). The research of M.R. is supported by research grants from FWF (project P32699) and the Austrian Research Promotion Agency (FFG, COMET Centre VASCage).
The University Hospital and Medical University of Innsbruck, Austria (M.R.) and Vienna, Austria (R.H. and T.B.) receive payments for antibody assays (MOG, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). H.L. declares no competing interests.
Peer review information
Nature Reviews Neurology thanks I. Nakashima and I. Metz for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Höftberger, R., Lassmann, H., Berger, T. et al. Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept. Nat Rev Neurol 18, 681–688 (2022). https://doi.org/10.1038/s41582-022-00700-2